A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)

#1726

Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1

Aim(s): to describe a case of advanced MCC in long term CR during immunotherapy with Avelumab

Materials and methods: A 60-year-old man was referred to our center in July 2015 for advanced MCC with nodes and skin lesions, after platinum-based chemo. A phase II, open-label, multicenter trial to investigate the activity and safety of avelumab in pts with advanced MCC was open for enrolment at our institution. The pt was eligible for treatment and started the treatment in August 2015

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pusceddu S

Authors: Femia D, Prinzi N, Vernieri C, Lo Russo G, Concas L,

Keywords: Merkel cell carcinoma, Avelumab,